Completed PHASE3 INTERVENTIONAL 2-arm NCT01649921

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis, a Randomised Double-blind Placebo-controlled Pilot (Phase IIIb) Study

Sponsor: Radboud University Medical Center

Conditions Sepsis Septic Shock

Interventions Interferon-gamma, Recombinant Saline 0.9%

Updated 7 times since 2017 Last updated: Sep 28, 2017 Started: Nov 30, 2012 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01649921, this PHASE3 trial focuses on Sepsis and Septic Shock and remains completed. Sponsored by Radboud University Medical Center, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2017 — Oct 2017 [monthly]

Unknown Status PHASE3

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands